April 2015

Mylan raises Perrigo offer, rejected again

Thursday, April 30, 2015

Perrigo has rejected a revised, increased offer from global pharmaceutical company Mylan to acquire Perrigo, a global over-the-counter consumer goods and pharmaceutical company. Under the newest offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.

[Read More]

PTC Therapeutics’ cancer stem cell program targeting BMI1 enters phase I

Thursday, April 30, 2015

PTC Therapeutics has announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a phase I study in patients with advanced solid tumors. The open-label, first-in-human study will investigate the safety and pharmacokinetics of PTC596, an orally available small molecule. PTC’s BMI1 program is supported by a collaboration with the Wellcome Trust.

[Read More]

Benitec Biopharma doses fifth patient, initiates additional trial site for hepatitis C trial

Thursday, April 30, 2015

Benitec Biopharma, a Sydney, Australia-based biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or “expressed RNAi,” has doesed the fifth patient in the company’s first-in-man, phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in cohort two.

[Read More]